Assisted dying
The Royal College of Pharmacy (RCPharm) takes a neutral stance on this topic; it is neither for nor against assisted dying.
Published: 15 October 2024
Updated: 3 November 2026
Assisting a person with a terminal condition to end their life at a time of their choosing (assisted dying), is an emotive and challenging subject.
Despite this neutral position, we maintain involvement in relevant legislative processes around this issue to ensure that the views of pharmacists are considered and that the content of any Bills brought in the future reflects pharmacy practice. We believe that any legislation must stipulate explicit legal protection for pharmacists. There must also be a conscience clause, so that pharmacists have the right to refuse to participate on any grounds.
Policy statement on assisted dying
Background and policy context
An increasing number of jurisdictions now permit some form of assisted dying, although legal models differ substantially.
Euthanasia and assisted dying are permitted in countries including the Netherlands, Belgium, Luxembourg, Spain and Canada.
Assisted suicide only is permitted in jurisdictions such as Switzerland, Germany and Austria.
Other regulated models have been introduced in Australia, parts of the United States and Colombia. Across all systems, eligibility criteria, safeguards and the extent of medical involvement vary, reflecting different legal and ethical approaches to assisted dying[1].
Related articles
Pharmacy 2030: a professional vision
Click on the links provided to download a PDF copy of the full vision or the executive summary.
Executive summary
Introduction
The vision: professional roles in pharmacy
Achieving the vision: underpinning infrastructure
Acknowledgments and strategic links
Introduction
Every health and care profession, every health service provider and every government has been influenced by the COVID-19 pandemic. It has caused everyone to reflect on whether the strategic directions set five or 10 years ago are still right for a post-pandemic future. Pharmacy is no different: it feels like the right time to set out a new professional vision, building on what has been developed previously to create something that describes the new future.
Describing a vision for the future is challenging: some pharmacy teams are already pushing boundaries and delivering care that for others seems a distant dream. What this vision recognises is that everyone is on a journey, and it aims to support all of pharmacy to move forward to a new level of professional practice. It is an evolution from where we are now, not a revolution.
The future of pharmacy
By 2030, the traditional boundaries between pharmacy sectors will be broken down. Pharmacy teams will work together, both within pharmacy and with the wider multidisciplinary team, to deliver seamless care for patients.
Pharmacy teams will take a person-centred approach and care will be provided holistically rather than by clinical condition. They will ensure high quality, safe, effective, cost-effective and sustainable prescribing in all settings. In addition, they will drive high standards of medicines governance, and ensure every aspect of prescribing and dispensing processes are effective and efficient.
For pharmacists, this will mean being recognised as medicines experts who take leadership of prescribing in all care settings and who optimise therapeutic outcomes for individual patients. There will be a shift away from checking other professionals’ work towards pharmacists having a clinical, prescribing role to manage the care of individual patients. Pharmacy technicians will lead medicines management processes, both in technical roles focused on the safe and efficient supply of medicines, and in patient-facing roles to support patients’ use of medicines.
The breaking down of boundaries between pharmacy sectors will be demonstrated through two key shifts. The first is that seamless patient care will be standard. As a patient moves between care settings, such as at hospital discharge, pharmacy teams will work together to ensure patients’ medicines-related care is supported and to avoid duplication of tasks in the patient’s journey. The second shift is that pharmacy will be more dynamic. Many pharmacy professionals are now actively seeking a portfolio career, working across different sectors. By 2030, a core generalist role for both pharmacists and pharmacy technicians will be developed to enable this flexible portfolio working.
This change will be driven by digital and technology developments to enable whole-team working, and clear pathways of professional development which apply to all sectors of pharmacy.
“Pharmacy will work together with patients and the multidisciplinary team, using their expertise to make the best use of medicines”
The vision: professional roles in pharmacy
Being the experts in medicines — "Ensuring the quality and safety of medicines use"
The key role of pharmacy professionals, that distinguishes them from other health care professions, is expertise in medicines. This will remain at the centre of pharmacy in 2030, with pharmacy teams ensuring the quality and safety of medicines use through both patient-facing and technical expertise.
In 2030, pharmacists will be the clinical lead for safe and effective prescribing within all care settings. Most pharmacists will work in patient-facing roles, consulting with patients: assessing, prescribing, monitoring and reviewing medicines for individual patients. They will be autonomous professionals working within multidisciplinary teams, prescribing in their own right, and managing caseloads of patients who take high risk medicines or who have complex therapeutic needs.
These pharmacists will be known as “advanced generalist pharmacists” and will be able to move flexibly between care settings. Some pharmacists will choose to specialise in particular clinical or technical fields, and will become “advanced specialist pharmacists”. Some will develop further into consultant pharmacists who have an influence beyond the individual service to leading whole system improvements.
In 2030, pharmacy technicians will lead and be experts in safe and secure purchasing, storage, dispensing and supply of medicines. This will include managing services and providing assurance on safe and effective processes. Pharmacy technicians working in patient-facing advanced level roles will consult with patients, undertake technical aspects of medicines reconciliation and medication review, triage patients, monitor and review blood results, provide patient education, administer medicines (if enabled by legislation/governance arrangements) and liaise with cross sector pharmacy teams.
Optimising therapeutic outcomes — Prescribing, monitoring, reviewing, adjusting and stopping medicines
n 2030, pharmacy teams will ensure every patient receives high quality prescribing of new medicines and timely, systematic medication reviews. All patients will receive the right care at the right time and the right place.
Therapeutic outcomes will be optimised through prescribing, monitoring, reviewing, adjusting and stopping medicines. Pharmacy input will be targeted at: key stages in a patient’s journey such as at transitions between care settings, when patients are acutely unwell, patients who receive high risk medicines and complex therapies, and frail patients. This will improve medicines safety, help manage risk and reduce unnecessary polypharmacy.
Optimising outcomes will include delivering greener, more environmentally sustainable services. Pharmacy teams will consider the environmental impact of medicines when prescribing and reviewing medicines, and take action to reduce medicines waste.
Providing person-centred holistic care — Empowering patients to make shared decisions about their medicines
The core role of pharmacy teams in 2030 will be to provide care for patients holistically, focused on the person rather than their clinical condition or medicines. They will enable person-centred care by having positive conversations with patients and their families/carers, and empowering patients to make shared decisions about their medicines and health.
Prescribing decisions will be taken using a Realistic Medicine approach by asking patients “what matters to you”. Pharmacy teams will have regular conversations with patients about medicines. These conversations will be enhanced by pharmacy teams being trained in effective, inclusive communication to address inequalities caused by low health literacy.
Pharmacy teams will have essential roles in preventing ill health by taking a holistic approach to care that goes beyond medicines. This will include the provision of health improvement services such as harm minimisation to reduce drug deaths, mental health support, brief interventions to reduce alcohol use, vaccination services and lifestyle advice including using a social/green prescription approach.
Improving access to care — Achieving equity of access to pharmacy services
Before 2030, all pharmacy teams will proactively offer services in a way that delivers equity of access. They will identify vulnerable patients who need specific support and adapt services for them.
A service of particular importance in improving access to care is the NHS Scotland Pharmacy First service: the public’s first port of call for common clinical conditions. By 2030, the vast majority of community pharmacists will be independent prescribers, enabling the Pharmacy First service to be further developed, and it will also be extended into populations who cannot currently access it.
By 2030, pharmacy services will be planned alongside wider NHS clinical service provision to ensure equitable access to pharmacy services is achieved across the 7-day period. This does not mean that a full pharmacy service is needed in all settings 24/7 but that patients requiring immediate care, particularly in hospital and out of hours services, are not disadvantaged by the day of the week or time they access services.
More generally, access will be improved by enabling services in the way patients want. Pharmacy teams will routinely offer patients a choice of remote consulting, asynchronous consultations and other digital services, as well as in-person care. Similarly, medicines supply will be offered by in-pharmacy collection, delivery services and remote collection, but in all cases, patients will have an opportunity to consult with a member of the pharmacy team, including a pharmacist, every time a medicine is supplied.
Leading medicines' governance — Ensuring high-quality prescribing, supply and use of medicines through robust governance
Pharmacy teams already play essential roles in medicines governance, focusing on ensuring the safe and effective use of medicines. The crucial difference between the future and today is that in 2030, this will be recognised by others as a leadership role. Currently pharmacy teams both define and implement medicines governance processes: in future, the wider health care team will be involved in implementing the processes.
Pharmacy teams will ensure standardised robust work processes, and good governance around the supply of medicines and high-quality evidence-based prescribing. They will consistently implement lean processes to achieve accurate prescribing, dispensing and use of medicines.
The supply of medicines will be modernised by 2030. Pharmacy technicians will be the professional leads for the assembly, distribution, and safe and effective supply of medicines. Pharmacists will continue to have an essential role in the medicines supply process through the clinical check. Every prescription for a medicine that is new or has been changed will be clinically checked by a pharmacist, and this will include a conversation with the patient. Accuracy checking will be automated through scanning technology to reduce workload and increase safety.
Leading evidence-based practice — Involved in research and strategic leadership to shape service development
The creation of a recognised evidence base to underpin the use of medicines and pharmacy practice will continue to be essential in 2030. By then, most pharmacists and pharmacy technicians will have developed research capability and will be involved in research, service development and quality improvement. Pharmacists working in academia and industry will play a leading role both in conducting research and in supporting the development of research skills in others.
This evidence will be essential in enabling pharmacists to develop prescribing guidance. By 2030, such guidance will include consideration of the environmental impact of different medicines. Altogether this work will reduce harm, waste and variation.
Pharmacists will also have an important role to play in strategic leadership to shape services and models of care in NHS boards and other organisations, wherever medicines are used.
Achieving the vision: underpinning infrastructure
Using data to deliver high-quality services — Data will underpin personalised care for patients and improved service planning
By 2030, data will be used to enhance pharmacy services in a number of ways.
Clinical data will be used to target and support decisions. Data will enable provision of personalised care and medicines for patients, including in pharmacogenomics. Decision support software, including artificial intelligence tools, will provide data that will be used to improve the quality and safety of care and prescribing.
Data will also be used to make population-based decisions to plan services and prioritise pharmacy resources in response to local needs. In 2030, a national dataset will be available, which will demonstrate the effectiveness and quality of pharmacy services in all settings, enabling the impact of pharmacy services on improving population health to be determined. Clinical outcome measures will be developed, linking patient outcomes with prescribing and administration data. In addition, systems will be developed for obtaining feedback from patients and colleagues about pharmacy teams’ performance to drive continuous service improvement.
Harness digital technology and innovation — A single shared electronic patient record will transform health and care services
The biggest digital transformation of pharmacy and health care by 2030 will be the introduction of a single shared electronic patient record across all health and care services. This will be a universal patient record into which every professional both reads and writes information, using their existing clinical system as the entry point. Each professional group will have a different view, according to what is appropriate for their role. This record will release clinicians’ capacity, improve safety and enable the provision of better care for patients.
Another significant digital development will be full electronic prescribing and transfer of prescriptions across all care settings, removing the need for paper prescriptions. Electronic systems will underpin the recording of administration of medicines in all relevant care settings, including hospitals, care homes, care at home services and prisons. Hospital Electronic Prescribing and Medicines Administration systems (HEPMA) will support triaging of patients to allow clinical pharmacists to target those high-risk patients who need pharmaceutical input as a priority.
Technology will also be harnessed to develop patient-facing services including digital consultations and remote monitoring.
Developing the workforce — Continual professional development will be embedded across the whole pharmacy workforce
By 2030, career development pathways will be in place for all members of the pharmacy team to support professional development, enabling people to flourish and feel fulfilled in their roles.
For pharmacists, professional development will be aligned to the RPS curricula for foundation, advanced and consultant practice. Some pharmacists will also choose to complete higher degrees. For pharmacy technicians, professional development will be shaped by a suite of frameworks similar to those for pharmacists. All patient-facing pharmacists will have advanced clinical assessment and consultation skills, and be independent prescribers.
Across both pharmacy professions, there will be a cultural shift to a system that is committed to continual professional development. All pharmacy professionals will have a role in supporting the education and development of others. Protected learning time and peer support networks will enable professional development and underpin reflective practice. Leading and participating in research and quality improvement will be a normal professional activity.
By 2030, the pharmacy workplace culture will be inclusive, celebrate diversity, create a sense of belonging and be supportive of team members’ wellbeing. Pharmacy professionals will have rest breaks during the working day, flexible working options including portfolio careers, access to wellbeing services and a proper work-life balance.
Workforce planning will be carried out across Scotland to ensure that the right skill mix and staffing levels are present in every pharmacy team. This will optimise the roles of pharmacy team members, maximise the time for clinical care, motivate staff and deliver optimal care for patients.
Delivering seamless care — All pharmacy professionals will work together across transitions of care
By 2030, all pharmacy professionals from all sectors will work together to deliver seamless transitions of care for patients as they move around the health service. Pharmacists will stop being described by their location but by their skills. Care will be planned around patients, for example transforming the supply of medicines on discharge from hospital so they are supplied by the patient’s community pharmacy instead of waiting in hospital.
Seamless care extends beyond pharmacy to the wider multidisciplinary health and social care team. Pharmacy will be embedded in multidisciplinary teams and will have well-established referral pathways in and out of pharmacy services. Pharmacy will also play a central role in the new National Care Service to ensure the safe and appropriate use of medicines in care services.
Acknowledgments and strategic links
Achieving the vision: Key enablers
Create a single shared patient record into which every professional both reads and writes information, using their existing clinical system as the entry point
Make electronic prescribing, transfer of prescriptions & medicines administration systems available in all settings
Improve skill mix within pharmacy teams, combined with effective workforce planning to ensure safe, effective and appropriate pharmacy staffing
Support all patient-facing pharmacists to train as independent prescribers
NHS Scotland to align the pharmacist post-registration development pathway to the RPS curricula for post-foundation, advanced and consultant practice; and equivalent professional development and credentialing pathways developed for pharmacy technicians
Introduce protected learning time for all pharmacy teams to enable professional development and research activities
Provide equipment to enable patient-facing digital services and training to maximise its use
Establish a national data set to demonstrate the effectiveness and quality of pharmacy services
Embed the use of data, such as pharmacogenomics, to help guide treatment decisions and deliver personalised medicine
Further embed pharmacy into the wider health and social care multidisciplinary team and develop clear referral pathways in and out of pharmacy services.
Acknowledgements
We are hugely grateful to all the pharmacists and pharmacy technicians across Scotland who contributed to this vision by participating in focus groups, and sharing their views through surveys, emails, phone calls and meetings.
We are also grateful to the pharmacy and non-pharmacy stakeholders who met with us through the consultation period and commented on numerous drafts. This vision was shaped by every single person who was involved: it could not have been created without them, and this final version belongs to them all.
Strategic links
To make this vision relevant to the strategic direction of travel in Scotland, documents produced by Scottish Government, NHS Scotland and other stakeholders were referenced.
The section below highlights some key quotes from some of these documents:
Achieving excellence in pharmaceutical care
“The evolving focus of pharmacy practice to ensure that people have an understanding of what to expect from their medication requires an acknowledgement that people and their carers rightly wish to be active partners in treatment options."
“Pharmacy resource can be targeted through a triage model, focusing on high risk and complex cases.”
“Hospital discharge can be a difficult time to support people with adherence to new medication regimens. There is a role for pharmacists and pharmacy technicians in supporting this transition by taking on a greater part in managing care prior to and during discharge.”
Scottish Government. 'Achieving excellence in pharmaceutical care: a strategy for Scotland'. August 2017.
Scotland’s national clinical strategy
“The contribution of pharmacists can be considerably enhanced, with their expertise in ensuring that people with complex medication regimes have their care optimised, and the potential for side effects or harmful interactions reduced."
Health care teams should “provide care that is person centred rather than condition focused.”
NHS services must “collect and use more information on outcomes, especially those that matter most to patients, rather than clinical data such as biochemical or other surrogate markers”.
“While medicines can bring great benefit, they can also cause significant harm. Older people tend to experience worse side effects or consequences of treatment. That is why we should strive to actively manage risk associated with polypharmacy by regularly reviewing and rationalising our patient’s medications.”
“Serious harm can result if we don’t listen to the people we care for, and if they are not given the information and support they need to make informed decisions about their care.”
“NHS Scotland is a significant contributor to the climate emergency. It emits a large amount of greenhouse gasses, consumes huge amounts of resources and produces copious amounts of waste. We have a moral obligation to help tackle the greatest threat to human health by reducing our impact on the environment. Responsibility rests with us all.”
Scottish Government. 'Recover, restore, renew — Chief Medical Officer for Scotland Annual Report 2020-2021'. March 2021
The ALLIANCE’s report on health and wellbeing priorities for the future
Care should be “flexible, person-centred which recognises the holistic nature of individuals” and that “being involved in the decision-making process and treated as an expert in their own life circumstances and care” is of the utmost importance to people.
“For many people the innovative and accelerated implementation of virtual services improved access, made it quicker and supported more choices for the individual. People have welcomed the use of this technology, and its wider implementation and use should continue.”
ALLIANCE. 'Health, wellbeing and the COVID-19 pandemic: Scottish experiences and priorities for the future'. February 2021.
The NHS Scotland recovery plan 2021-26
“We will design services so that we minimise unnecessary travel and increase the focus on ‘net-zero’ approaches.”
“We will continue to support the move to more health care being provided in the community and closer to home.”
We will design a new sustainable system, focused on reducing inequality and improving health and wellbeing outcomes, and sustainable communities."
“We will develop and introduce a new pharmacy woman’s health and wellbeing service through our public health services.”
“We will also establish a community pharmacy hospital discharge and medicines reconciliation service to help speed up the process for people being discharged from hospital.”
“We are investing in developing new digital solutions such as ePrescribing and eDispensing to make the prescribing process paperless.”
Scottish Government. 'NHS recovery plan 2021-26'. August 2021
Scottish polypharmacy guidance
“With up to 11% of unplanned hospital admissions being attributable to harm from medicines and over 70% of these being due to elderly patients on multiple medicines, there are significant opportunities to reduce this burden by timely and effective interventions.”
Scottish Government. 'Polypharmacy guidance — realistic prescribing', Third edition, 2018.
Medicines shortage policy
A legal framework is needed across Great Britain to allow community pharmacists to make professional decisions and take appropriate steps to supply medicines to patients during times of medicines shortages.
Over the last two years, (as the Royal Pharmaceutical Society) we undertook extensive advocacy work to represent the interests and perspectives of pharmacists on this issue; engaging with the UK Parliament in Westminster and the Scottish Parliament in Holyrood when the Terminally Ill Adults (End of Life) Bill and the Assisted Dying for Terminally Ill Adults (Scotland) Bill passed through the legislative process. Neither Bill became law[2][3].
In the event these laws are ever passed, every pharmacist would need to make a personal decision on whether or not they would wish to be involved in providing or supporting such a service.
The Royal College of Pharmacy is the professional body representing pharmacists in all sectors of the pharmacy profession. As such, there is a wide spectrum of members views to be considered and respected.
Policy objectives
This policy outlines our approach to the issues and challenges which the pharmacy profession would be presented with should assisted dying be legalised. It respects the views of individual pharmacists by providing suitable principles for those who wish to be involved, to work in partnership with the multidisciplinary team, whilst providing reassurance for those pharmacists opposed to assisted dying.
The suggested principles outlined below demonstrate that the views, expressed by those for and against the concept, have been acknowledged and considered in developing our position. The principles take account of the issues that need to be addressed before a prescription to end a person’s life can be dispensed and seeks to ensure that patient access to the service is not compromised by inadequate signposting or service provision.
This document is a policy statement and is not intended as practice guidance. It is not meant to be definitive or overly prescriptive as the finer details of practice and procedure will still need to be developed depending on the exact nature of any new legislation. Fuller debate will also be required to accommodate patients’ needs in a variety of settings across all the home countries of Great Britain.
The document seeks to provide information and a clear direction on the requirements of the pharmacy profession to government policymakers, other professional bodies, health and social care colleagues, patients, the public and other key stakeholders. It has evolved with learning generated from engagement with this topic over recent years.
If legislation is passed, pharmacists will have a key role in developing suitable protocols and guidance for prescribers and other healthcare professionals. Policymakers must recognise and be aware that the role of pharmacists goes far beyond supply of the approved substance.
The RCPharm will work closely with policymakers and legislators to ensure that any legislation, and subsequent regulations, give careful consideration to the principles outlined in this policy. There is a professional duty to handle any conversations and interactions on this topic with compassion, sensitivity and respect. The UK Chief Pharmaceutical Officers have given advice to help pharmacists and pharmacy technicians who wish to take part in the assisted dying debate[4].
Proposals for changes in the law have sought to address solely the situation of a mentally competent person suffering from a terminal condition, whose quality of life has deteriorated to the extent that they now determine it to be intolerable and that they wish to end their life at a time of their choosing, rather than by the natural course of their disease. It is therefore in this context that we are specifically examining the issues around assisted dying from a pharmacy perspective and have not yet addressed the wider issue of either euthanasia or a broader patient group.
Definitions
Assisted dying – A term used to describe the process, initiated by a person voluntarily, who is dying and wishes to end their own life; which includes the assessment of eligibility amongst other requirements and prescription of an approved substance, which the person self-administers to bring about their own death. This term may also include Physician Assisted Dying or Physician Assisted Suicide, where the approved substance is administered by a physician rather than the person requesting assisted death. (Illegal in the UK at present)
Voluntary euthanasia – where one person makes a conscious decision to die and asks for help from another person to do so (illegal in the UK at present and there are no moves to change this position)[5].
Mental capacity – A person is considered mentally capable if they fit with the definitions of the Mental Capacity Act (England and Wales) 2005 and the Adults with Incapacity (Scotland) Act 2000[6][7].
Principles
Conscience clause – It is essential that a conscience clause is incorporated into any legislation. Pharmacists must have the legal protection to refuse to participate in any aspect of the process, on any grounds. No pharmacist should experience any form of detriment for exercising this right. Our view is that pharmacists should be able to ‘opt in’ by completing the necessary training, rather than ‘opting out’. It also avoids the need for anyone who does not wish to participate to signpost to another pharmacist as this could also pose an ethical dilemma.
Legal protection – There must be explicit protection in place in any legislation for pharmacists, pharmacy technicians and other health care professionals to be protected from prosecution when participating in the approved process for an assisted dying procedure. We would not anticipate any non-regulated pharmacy support staff to be involved in any of these procedures.
Criteria – All safeguards initially agreed in any prospective legislation need to be effective and rigorously applied. The criteria for eligibility should be steadfast and unable to be altered without proceeding through the primary legislative process.
Public or Private – If assisted dying were to become law, it should remain within the NHS, following the principles of equity of access and consistency and should not be shaped by commercial interests in the independent healthcare sector.
Mental capacity and eligibility – Mental capacity is fundamental to any decision about assisted dying. A person must be able to make an informed, voluntary choice, including understanding the nature and consequences of the decision and retaining the ability to change their mind at any stage. This requirement means that individuals who lack capacity, such as those with advanced dementia or Alzheimer’s disease, would be excluded, even though these are terminal conditions. This is a critical safeguard for any assisted dying process.
Palliative and End-of-Life Care – Requests for assisted dying should never be considered in isolation from the palliative and end-of-life care available. It cannot be assumed that such a request reflects a person’s true or informed preference; in some cases, it may arise from unmet needs, poor symptom control, or a lack of awareness of the support and treatment options available. Ensuring access to high-quality, person-centred palliative care is therefore essential, with a multidisciplinary and holistic approach that explores all physical, psychological, and social aspects of care.
Before any consideration of assisted dying, individuals should receive clear counselling and comprehensive information about all available alternatives. This includes detailed discussion of pain and symptom management, psychosocial support, and advances in palliative care that can significantly improve quality of life at the end of life. Patients must also be supported to understand the assisted dying process itself, including its implications, risks, and limitations, so that any decision is fully informed.
As experts in medicines, pharmacists are central to optimising symptom control, undertaking medication reviews, and addressing polypharmacy—particularly important in reducing side effects and improving comfort in the final stages of life. They contribute to ensuring safe, effective, and appropriate use of medicines, while also supporting patients and families with advice, reassurance, and education about treatment options.
Palliative care pharmacists have valuable expertise for developing protocols, but their involvement in assisted dying should not be assumed and may present conflicts of interest. Some, particularly in hospice settings, may choose not to participate due to concerns about patient and family perceptions.
All appropriate alternatives should be carefully considered and explored with a person requesting assisted dying. Evidence from services such as Dignitas suggests that access to information and supportive care can lead some individuals to pursue alternatives to assisted death[8]. This reinforces the importance of prioritising high-quality palliative care, with pharmacists as key contributors to delivering compassionate, safe, and holistic end-of-life support.
Established treatment pathways at the end of life should remain quite separate from a formal assisted dying procedure.
Assistance – A person must be able to self-administer the approved substance and be able to change their mind and halt the procedure at any point, to differentiate between assisted dying and euthanasia. A person’s physical state might deteriorate between making their decision to end their life and the date planned for the procedure.
Medical devices may be required to overcome physical limitations arising from an existing condition or the terminal illness. These needs should be clearly identified and addressed within the assisted dying care plan.
Assessment – Two doctors should carry out a full assessment of the patient, which carries the responsibility for ensuring that the patient fits the necessary eligibility criteria before an approved substance can be prescribed. All relevant medical records must be available to both assessors.
National approach – Despite the devolved nature of healthcare and legislation related to assisted dying, national guidance and protocols would be expected to be in place to ensure that best practice for the procedure is consistently applied across Great Britain. It would be necessary to look at all the available evidence and experience of other countries in developing protocols for pathways involving approved substances.
Similar protocols and procedures should be in place no matter in which setting the patient is being cared for. This would include hospital, hospice, care home, the patient’s own home and any other domiciliary setting. The protocol should also cover the issue of prescriptions, supply, documented use and return and disposal of any unused approved substances. In addition, we would expect there to be provisions for the manufacture, importation, distribution, storage, preparation and assembly of the approved substance. A robust audit trail is required.
Pharmacists must be included in any multidisciplinary working group to develop national guidance for all settings. The group membership should also include representation from the controlled drugs accountable officers’ network, particularly if controlled drugs are being considered for use.
Registration with a GP in the country where the procedure is lawful and is to be carried out would also be required.
Patient care
Once the final request has been made by the patient and the necessary processes are complete as laid down within the law, arrangements would be made for the supply of the approved substance as laid out in the agreed protocols and procedures.
Close cooperation between pharmacy and medical colleagues would be required to facilitate all the necessary arrangements and ensure all documentation is in place before any supply is made. The timing and administration details require careful consideration to avoid patients requesting a procedure ahead of their own particular need to satisfy protocol and administrative requirements.
A person-centred approach is crucial for all aspects of assisted dying and people may change their mind. It is vital that the person can indicate their wishes until the final moments of their life.
Service arrangements should be sufficiently flexible to ensure equitable access across different geographical areas, recognising that the availability of healthcare professionals, including pharmacists who have opted to participate, may vary by locality.
A person’s wishes around confidentiality and the number of people party to the process need to be accommodated. Families and carers should not be subjected to any unnecessary pressure and stress at such an emotional time. They may or may not want to be involved in the practicalities of arranging a procedure.
Patients should be able to talk to any healthcare professional about assisted dying and be advised or signposted accordingly. A mechanism to support the identification of healthcare professionals who have opted in to the service, such as a register, will be important to support patient choice, planning and access to clear, robust and reliable procedures. This should include contingency planning for occurrences where original personnel were to be unavailable for any reason.
Prescribing and dispensing
A pharmacist assumes a proportion of the responsibility for any approved substance or medicine supplied and therefore must be assured that all legal requirements are in place and that it is entirely appropriate for the patient.
In addition to the usual practice of checking that the prescription fulfils the necessary legal requirements, pharmacists must have full access to the patient’s diagnosis and assisted dying documentation. As with any medicine supply, pharmacists hold a clear professional and legal accountability to ensure the dispensing activities for an approved substance comply with all legal requirements and regulatory standards. This will include verifying the validity of authorising documentation, including consent, ideally before the day of dispensing. Procedures must be in place to ensure that a pharmacist may raise a concern if they believe the patient has been coerced or has changed their mind. Close liaison between the doctor (or authorised person) and pharmacist will be necessary to ensure smooth and robust processes including safe storage, preparation, collection, return and safe disposal.
Accurate records will be required to ensure a robust audit trail and compliance with any regulations on record keeping and data analysis.
Consideration must be given to the appropriate timing of the request for the substance. Validity of prescriptions as well as the time taken for the pharmacist to review the necessary paperwork and the time between ordering and delivery, all must be taken into account when processes are produced. The exact details of this process will be dependent on any future model which may be chosen to facilitate assisted dying.
It is unclear whether any approved substances used for this procedure will have a marketing authorisation (MA) in the UK for human use or have an MA but will be used off-label rather than for the licensed indication. While this should not present any difficulties, the doctor, patient and pharmacist should be aware of this.
Training and education
In order to balance the needs of confidentiality and access to services, we advocate that pharmacists indicate their willingness to be involved by “opting in” to training and then be listed on a database alongside other healthcare professionals who would take part. Pharmacists who do not wish to be involved would not be listed and therefore would not be approached.
Pharmacists would need to be fully competent in the legal requirements of an assisted dying procedure and have knowledge of the necessary documentation, consent requirements and protocols. Joint training with other disciplines involved would be necessary to give a coordinated approach and common understanding of the process.
It would be advantageous for any training to be holistic in nature and encompass some of the sensitivities pharmacists may encounter in practice. Training in advanced communication for end-of-life care, cultural attitudes towards death and dying and how to raise concerns if there is a suspicion of coercion will be important. Pharmacists may also require psychological support, and this might extend to the provision of peer support for colleagues or signposting to the Listening Friends service from Pharmacist Support if required.
This training would also be available to pharmacy technicians. Training would always be optional, aligning with the conscience clause, but successful completion of the training would be mandatory before any involvement in an assisted dying procedure commences.
Organisations involved in the education and training of pharmacists and pharmacy technicians, namely Public Services Delivery Scotland Pharmacy, Centre for Pharmacy Postgraduate Education (CPPE) and Health Education and Improvement Wales (HEIW), would be key participants in supporting the development and delivery of educational packages whilst ensuring a coordinated national approach is adopted across GB.
Role of the pharmacist in any Assisted Death Procedure
Pharmacists will play a key role in supplying approved substances for assisted dying. However, subject to legislative models of care, this role could extend beyond supply to a more patient‑centred function, supporting the safe and effective use of the substance, including at the point of assisted death.
Other activities associated with assisted dying could include, but not be limited to:
- The manufacture or preparation of the “approved substance”;
- Dispensing, transportation and supply of the approved substance, including as part of the wider supply chain;
- Advice on how to enable a person to self-administer the approved substance;
- Developing protocols and guidance for prescribers;
- Potential return and safe disposal of the approved substance.
Policy drafting process
In 2013, an expert working group was established with a cross-sector representation of pharmacists with expertise in many aspects of practice, including legal and ethical, palliative care, oncology, controlled drug accountable officers, hospices, education, primary care, community and hospital practice. Initial views from the working group were sought via a webinar and then disseminated to a wider reference group for feedback and comment. Members’ views were also sought through a virtual network discussion and coverage in the Pharmaceutical Journal.
In 2019, by invitation, Baroness Meacher, the Chair of Dignity in Dying, reviewed the terminology and language used within the policy.
In 2021, the policy was once again reviewed and the introduction updated to reflect the more recent activity around the subject. The document was then reviewed by the then Royal Pharmaceutical Society Boards in England, Scotland and Wales.
In 2024, a further review was completed following the introduction of the Assisted Dying for Terminally Ill Adults (Scotland) Bill and the decision in Jersey to proceed to law drafting for assisted dying for those with a terminal illness by the States Assembly.
In 2026, this policy was reviewed again, reflecting the considerable activity at both Westminster and Holyrood on Assisted Dying legislation. The updated policy was reviewed and approved by the National Pharmacy Advisory Councils of the Royal College of Pharmacy.
We have attempted to be as inclusive as possible in the drafting process but recognise that this policy statement cannot fully encompass the breadth of opinions held, in good conscience, by all our membership. Feedback from our members is always encouraged, and the policy will be kept under review.
September 2026
References- LegalClarity. What countries allow assisted suicide and euthanasia? [Internet]. 2026. Available from: ↩︎
- Royal College of Pharmacy. Statement: assisted dying for terminally ill adults (Scotland) bill [Internet]. 2026. Available from: ↩︎
- The Pharmaceutical Journal,. Burns C. House of Commons passes amendment allowing pharmacists to opt out of assisted dying process [Internet]. 2025. Available from: ↩︎
- UK Chief Pharmaceutical Officers. Assisted dying bill debate: advice to pharmacists and pharmacy technicians from the UK Chief Pharmaceutical Officers [Internet]. 2024. Available from: ↩︎
- NHS. Euthanasia and assisted suicide [Internet]. 2023. Available from: ↩︎
- NHS. Mental Capacity Act [Internet]. 2024. Available from: ↩︎
- Scottish Parliament. Adults with Incapacity (Scotland) Act 2000 [Internet]. 2000. Available from: ↩︎
- Dignitas (n.d.). So funkioniert Dignitas [Internet]. 2014. Available from: ↩︎